Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fmed.2021.689539 http://scihub22266oqcxt.onion/10.3389/fmed.2021.689539 34336892!8322657!34336892     free     free     free       Front+Med+(Lausanne) 2021 ; 8 (ä): 689539 Nephropedia Template TP {{tp|p=34336892|t=2021. Treatment of COVID-19 in Patients With Sarcoidosis |pdf=|usr=}}{{34336892}} gab.com Text Treatment of COVID-19 in Patients With Sarcoidosis JO: Front Med (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=34336892 #FOAvip Recent case reports and studies on treating COVID-19 in patients with chronic sarcoidosis describe different treatment modalities ranging from glucocorticoids to biologic medications. This review article summarizes seven case series and reports totaling 46 patients. While one case report suggested that sarcoidosis medications such as glucocorticoids may lengthen the COVID-19 disease course, another study with a larger registry suggests they do not. More studies are needed to elucidate an improvement in outcomes. It is possible that addition of TNF-alpha inhibitors at COVID-19 diagnosis decreases hospitalization rate. Overall, it is difficult to make firm conclusions regarding treatment given the heterogeneity of treatment modalities in the current literature. Our summarized findings are outlined with the opinions of sarcoidosis, pulmonary, and infectious disease experts in a flow chart that provides clinicians with our proposed management algorithm for sarcoidosis patients who develop COVID-19. We emphasize a need for exchange of information regarding management of COVID-19 in the setting of sarcoidosis to further improve treatment in this vulnerable population of patients. Twit Text FOAVip Treatment of COVID-19 in Patients With Sarcoidosis ????Front Med (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=34336892 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34336892 #FOAvip English Wikipedia <ref>{{Cite pmid|34336892}}</ref> Treatment of COVID-19 in Patients With Sarcoidosis #MMPMID34336892 Kondle S; Hou T; Manansala M; Ascoli C; Novak RM; Sweiss N Front Med (Lausanne) 2021[]; 8 (ä): 689539 PMID34336892show ga Recent case reports and studies on treating COVID-19 in patients with chronic sarcoidosis describe different treatment modalities ranging from glucocorticoids to biologic medications. This review article summarizes seven case series and reports totaling 46 patients. While one case report suggested that sarcoidosis medications such as glucocorticoids may lengthen the COVID-19 disease course, another study with a larger registry suggests they do not. More studies are needed to elucidate an improvement in outcomes. It is possible that addition of TNF-alpha inhibitors at COVID-19 diagnosis decreases hospitalization rate. Overall, it is difficult to make firm conclusions regarding treatment given the heterogeneity of treatment modalities in the current literature. Our summarized findings are outlined with the opinions of sarcoidosis, pulmonary, and infectious disease experts in a flow chart that provides clinicians with our proposed management algorithm for sarcoidosis patients who develop COVID-19. We emphasize a need for exchange of information regarding management of COVID-19 in the setting of sarcoidosis to further improve treatment in this vulnerable population of patients. äTreatment of COVID-19 in Patients With Sarcoidosis (epmc).pdf DeepDyve Pubget Overpricing